Next Phase’s focus is the treatment of Psoriasis and Atopic Dermatitis, chronic non-contagious autoimmune dermatological diseases.

Psoriasis affects around 2-3% of the global population which represents around 150M people. Atopic Dermatitis affects around 300M people globally, the majority remaining undiagnosed or underserved by current therapies. These diseases usually present important comorbidities and a strong impact on the quality of life of patients making the need for new therapies to manage these conditions that much more important.

The global psoriasis treatment market is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% in the forecast period. Also, the global atopic dermatitis market size was valued at USD 11.77 billion in 2022. It is expected to grow at a CAGR of 13.13% and be worth USD 21.80 billion by 2027.



Current Therapeutic Landscape and NextPhase Solution:

The current therapeutic landscape for both psoriasis and atopic dermatitis can include both topical and systemic treatments. Steroids are the most common first line of treatment but can only be used for limited periods due to local and systemic effects (e.g., skin thinning, adrenal suppression). Biologics and other systemic treatments are expensive, most need prior authorization, have significant health risks and most require complex logistics for administration.

NextPhase’s exosome-based therapy will be a first-line treatment that combines the effectiveness of the best existing therapies while minimizing, if not eliminating, the safety risks. This will be a game changer as it will enable clinicians to manage the disease and complement other therapies.

Clinicians are looking for topical therapies with high effectiveness and lower safety risks.  Existing topical therapies (mostly steroids) are viewed as effective but of limited use to safety concerns. Before progressing to more complex therapies (eg. biologics and systemic) with higher costs, our survey suggests a real desire for additional options to manage disease progression.